Zaosng Zheng

Dr. Zaosng Zheng


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2024 in Drug Resistance Updates
Verified
Journal Article
Closed access
XZXiangbo Zeng
Xiangbo Zeng
ZCZhiliang Chen
Zhiliang Chen
YZYuanchao Zhu
Yuanchao Zhu
LLLei Liu
Lei Liu
ZZZhiyong Zhang
Zhiyong Zhang
ZZZaosng Zheng
Zaosng Zheng

3 May 2025 in Journal of the National Cancer Center
Verified
Journal Article
Open access
ZZZhiyong Zhang
Zhiyong Zhang
YXYingwei Xie
Yingwei Xie
LLLei Liu
Lei Liu
YWYongtao Wang
Yongtao Wang
SLShuang Li
Shuang Li
ZZZaosng Zheng
Zaosng Zheng
Genitourinary cancers constitute a significant portion of the global cancer burden and have emerged as a prominent cause of cancer-related mortality. However, there remains a paucity of up-to-date statistical analyses that meticulously examine the global and national shifts in the epidemiology of genitourinary cancers. Our study aimed to provide a comprehensive understanding of the global distribution and progression of genitourinary cancers through analyses of the recently updated 2021 Global Burden of Disease (GBD) database. This study presented the incidence, mortality, disability-adjusted life years (DALYs), and their respective age-standardized rates for four genitourinary cancers (bladder, kidney, prostate, and testicular cancers) by sex, age, and location from 1990 to 2021. Estimates for these data were presented with their 95% uncertainty intervals (UIs). Estimated annual percentage changes (EAPCs) and Bayesian Age-Period-Cohort (BAPC) models were utilized to further quantify the temporal dynamics of age-standardized rates (ASRs) in genitourinary cancers. Countries and territories were categorized according to socio-demographic index (SDI) quintiles. Globally, with the exception of a sustained decline in age-standardized incidence rates (ASIRs) for bladder cancer (EAPC = −0.36%), the ASIRs for kidney, prostate, and testicular cancers demonstrated an upward trend from 1990 to 2021 (EAPC = 0.53%, 0.20%, and 1.43%, respectively). In terms of geographical regions, High-income North America had the highest ASIRs for both bladder (13.98 per 100,000 persons [95% UI, 12.96 to 14.61]) and prostate (47.02 per 100,000 persons [95% UI, 44.47 to 49.04]) cancers. Southern Latin America recorded the highest ASIRs for kidney (13.44 per 100,000 persons [95% UI, 12.27 to 14.73]) and testicular (4.98 per 100,000 persons [95% UI, 4.33 to 5.72]) cancers. Additionally, Central Europe (1.25% [95% CI, 1.12% to 1.38%]), East Asia (2.40% [95% CI, 2.21% to 2.59%]), Eastern Europe (3.74% [95% CI, 3.55% to 3.92%]), and the Caribbean (5.52% [95% CI, 4.32% to 6.74%]) exhibited the highest EAPCs for bladder, kidney, prostate, and testicular cancers, respectively. Unlike the ASIRs, age-standardized mortality rates (ASMRs) and age-standardized DALYs rates (ASDRs) showed a downward trend over time in all types of genitourinary cancers. The disease burdens of bladder, kidney, and prostate cancers were primarily distributed among older men, while testicular cancer mainly occurred in young men. Smoking remained the primary risk factor for bladder cancer. Meanwhile, high fasting plasma glucose and high body-mass index exerted increasingly significant impacts on bladder and kidney cancers, respectively, during the study period. Projections to 2050 suggest that the global burdens of genitourinary cancers are expected to decline to varying degrees. However, regional disparities in genitourinary cancer burdens are projected to persist. Although the results demonstrate a marginal decline in ASRs caused by genitourinary cancers, they still impose a considerable global burden and result in numerous deaths. Our study obtained and analyzed the latest epidemiological data of genitourinary cancers from the GBD 2021, offering valuable information for national healthcare professionals and policymakers to optimize resource allocation, manage costs more efficiently, and develop practical healthcare policies.

29 March 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
CHChenxi Hu
Chenxi Hu
XZXiangbo Zeng
Xiangbo Zeng
YZYuanchao Zhu
Yuanchao Zhu
ZHZehai Huang
Zehai Huang
JLJiacheng Liu
Jiacheng Liu
WTWanlong Tan
Wanlong Tan
As a special pattern of programmed cell death, ferroptosis is reported to participate in several processes of tumor progression, including regulating proliferation, suppressing apoptotic pathways, increasing metastasis, and acquiring drug resistance. The marked features of ferroptosis are an abnormal intracellular iron metabolism and lipid peroxidation that are pluralistically modulated by ferroptosis-related molecules and signals, such as iron metabolism, lipid peroxidation, system Xc−, GPX4, ROS production, and Nrf2 signals. Non-coding RNAs (ncRNAs) are a type of functional RNA molecules that are not translated into a protein. Increasing studies demonstrate that ncRNAs have a diversity of regulatory roles in ferroptosis, thus influencing the progression of cancers. In this study, we review the fundamental mechanisms and regulation network of ncRNAs on ferroptosis in various tumors, aiming to provide a systematic understanding of recently emerging non-coding RNAs and ferroptosis.

30 May 2025 in International Journal of Surgery
Verified
Journal Article
Open access
ZZZhiyong Zhang
Zhiyong Zhang
YZYuanchao Zhu
Yuanchao Zhu
FZFengjin Zhao
Fengjin Zhao
SLShuang Li
Shuang Li
WDWei Dong
Wei Dong
ZZZaosng Zheng
Zaosng Zheng
Background: Genitourinary diseases significantly affect the quality of life of elderly individuals in Europe, yet comprehensive studies on their burden remain limited. This study used Global Burden of Disease (GBD) 2021 data to analyze the burden of genitourinary diseases in adults aged 55 and older in Europe from 1990 to 2021, with projections to 2030 to inform policy development. Materials and methods: Using GBD 2021 data, we assessed the burden of genitourinary diseases in European adults aged 55 and older, analyzing incidence, prevalence, mortality, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) rates. Associations with socioeconomic indicators, including the Socio-Demographic Index and Human Development Index (HDI), were analyzed using Spearman’s correlation. Temporal trends were examined through Estimated Annual Percentage Change and Autoregressive Integrated Moving Average models. Results: In 2021, Europe emerged as the region with the highest proportion of elderly populations globally. Among European nations, the Russian Federation reported the highest incidence rates of certain genitourinary diseases, including urinary tract infections (UTI) and interstitial nephritis (IN) at 10188.73 (95% UI 8549.59–11914.66), urolithiasis at 8538.61 (95% UI 6976.70–10,315.88), and benign prostatic hyperplasia at 1377.63 (95% UI 1040.48–1702.85) per 100 000 population. Greece exhibited the highest DALYs, mortality, and YLL rates related to chronic kidney disease. Notable gender and age disparities were evident, with males generally bearing a heavier burden across the majority of genitourinary disorders, except for UTI and IN, where females, particularly those aged 55–64, demonstrated a higher incidence. Socioeconomic factors also impacted these burdens, with higher HDI scores associated with increased mortality (R = 0.50, P < 0.001) and YLDs (R = 0.37, P = 0.014). Projections indicated that the burden of genitourinary diseases would continue to rise across most European countries over the next decade, while countries like Poland and Iceland were expected to experience declines. Conclusion: Genitourinary diseases are increasingly burdening Europe’s aging population. Addressing regional, gender, and socioeconomic disparities is critical for developing effective, age-sensitive healthcare policies and strengthening healthcare systems.

22 October 2025 in JCI Insight
Verified
Journal Article
Open access
YYYuzhong Ye
Yuzhong Ye
CYChangjie Yue
Changjie Yue
ZZZaosng Zheng
Zaosng Zheng
HRHailong Ruan
Hailong Ruan
YZYuanpeng Zhang
Yuanpeng Zhang
LLLei Liu
Lei Liu
Apoptosis and necroptosis are 2 distinct destinies of cells stimulated with TNF-α; however, it remains unclear how apoptosis and necroptosis are differentially regulated. This study validates the key regulatory role of speckle-type POZ protein (SPOP) in balancing apoptosis and necroptosis. SPOP promotes the polyubiquitination and degradation of receptor-interacting serine/threonine-protein kinase 3 (RIPK3), thereby inhibiting necrosome formation and decreasing cellular sensitivity to necroptosis. Conversely, SPOP interacted with RIPK1 independently of its E3 ubiquitin ligase activity, protecting it from ubiquitination and degradation, thereby enhancing RIPK1 expression and cellular sensitivity to apoptosis. Inhibiting RIPK1 kinase activity with 7-Cl-O-Nec-1 impeded both SPOP-mediated apoptosis and SPOP deficiency–mediated necroptosis. Besides, inhibition or loss of RIPK3 rescued SPOP deficiency–mediated necroptosis. Pancancer analyses indicated that the SPOP/RIPK1/RIPK3 axis is dysfunctional in a variety of tumors. In 3 representative tumor types with high expression of SPOP and RIPK1, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, and breast invasive carcinoma, this regulatory mechanism remains applicable. Based on these findings, a combination therapy using the second mitochondria-derived activator of caspases (Smac) mimetic SM164 and sunitinib was developed, demonstrating a more pronounced efficacy than sunitinib monotherapy, and this sensitizing effect was dependent on the expression level of RIPK1. These results suggest that the combination of Smac mimetics with tyrosine kinase inhibitors holds potential clinical value for tumors with dysregulated SPOP/RIPK1/RIPK3 signaling.

1 July 2026 in Autophagy
Verified
Journal Article
Closed access
XZXiangbo Zeng
Xiangbo Zeng
YZYuanchao Zhu
Yuanchao Zhu
YXYongyuan Xiao
Yongyuan Xiao
ZZZhiyong Zhang
Zhiyong Zhang
XCXiaoliang Chen
Xiaoliang Chen
ZZZaosng Zheng
Zaosng Zheng
Macroautophagy/autophagy is an evolutionarily conserved degradation pathway wherein cytoplasmic components are sequestered within double-membrane autophagosomes for lysosomal delivery. The initiation of autophagy is governed by autophagy-related (ATG) proteins, with the ULK1 kinase complex serving as the most upstream regulator. However, how ULK1 senses and integrates metabolic signals via post-translational modifications remains poorly understood. Here, we discover that ULK1 undergoes lactylation at lysine 46, catalyzed by the mitochondrial aminoacyl-tRNA synthetase AARS2, in response to autophagic stimuli. This modification promotes ULK1 kinase activity, leading to enhanced and selective phosphorylation of its downstream substrate ATG14 at Ser29, thereby activating the class III PtdIns3K complex and facilitating autophagosome biogenesis. Furthermore, we demonstrate that AARS2-mediated ULK1 lactylation drives autophagic flux and promotes tumor metastasis in clear cell renal cell carcinoma (ccRCC), and that a cell-penetrating peptide targeting K46 lactylation suppresses ccRCC progression in vitro and in vivo. Our study identifies lactylation as a novel regulatory mechanism controlling autophagy initiation and suggests that targeting AARS2-mediated ULK1 lactylation could be a potential strategy for treating ccRCC.